Herrmann Einsele

Publications (2)5.23 Total impact

• Source

  Available from: PubMed Central

  Article: DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.

  Martin Kropff, Peter Liebisch, Stefan Knop, Katja Weisel, Hannes Wand, Claudia-Nanette Gann, Wolfgang E Berdel, Herrmann Einsele
  [show abstract] [hide abstract]
  ABSTRACT: A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1. The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2). At this dose level, 92% of patients achieved at least a partial response. The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate. No patient experienced progressive disease. The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy. The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.
  Annals of Hematology 04/2009; 88(11):1125-30. · 2.62 Impact Factor
• Source

  Available from: Utz Krug

  Article: Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

  Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, Oliver A Cornely, Herrmann Einsele, Ruxandra Enzensberger, Holger Hebart, Werner Heinz, Christian Junghanss, Meinolf Karthaus, William Krüger, Utz Krug, Thomas Kubin, Olaf Penack, Dietmar Reichert, Stefan Reuter, Gerda Silling, Thomas Südhoff, Andrew J Ullmann, Georg Maschmeyer
  [show abstract] [hide abstract]
  ABSTRACT: Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive Candida infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection.
  Annals of Hematology 11/2008; 88(2):97-110. · 2.62 Impact Factor